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I n modern times, obesity has become a “pandem-ic” of global and growing proportions. In the general population, obesity is associated with 
increased mortality.1 Obese individuals have a high-
er incidence of cardiovascular risk factors, such as 
hypertension, dyslipidemia and diabetes mellitus. 
Therefore, this group of patients has higher morbidity 
and mortality associated with diseases of the cardio-
vascular system. Because weight reduction is associ-
ated with an improved cardiovascular risk profile, the 
guidelines for the primary prevention of cardiovas-
cular disease recommend weight reduction in over-
weight and obese patients.2 Despite the limited sci-
entific data, these recommendations have also been 
expanded to the guidelines for coronary artery dis-
ease3,4 and heart failure.5
The effects of obesity on the cardiovascular sys-
tem are varied and include increased insulin resis-
tance, elevated blood pressure, systemic inflamma-
tion and procoagulant state, dyslipidaemia, increased 
sympathetic activity, heart failure, endothelial dys-
function, coronary artery disease, atrial fibrillation, 
stroke, and systolic and diastolic dysfunction.6 There-
fore, recent guidelines for the primary prevention of 
coronary heart disease recommend a reduction in 
body weight in overweight and obese patients.6
In fact, epidemiological data suggest a protective 
role of obesity against some common diseases. It was 
first observed that obesity is a favorable prognostic 
factor in patients with end-stage renal failure.6 Thus 
was created the concept of the “obesity paradox”. In 
addition, the “obesity paradox” arose in diseases such 
as heart failure,7 atrial fibrillation,8 sudden cardiac 
death,9 and coronary artery disease.10
The effect of the “obesity paradox” is also appar-
ent in patients with acute coronary syndromes (ACS). 
In particular, the MADIT II study found an inverse cor-
relation between body mass index (BMI) and total mor-
tality and sudden cardiac death in patients with systolic 
dysfunction after acute myocardial infarction (AMI).7,8
Moreover, a recent meta-analysis of several stud-
ies by Niedjela et al8 found that both overweight and 
obese patients had lower mortality after AMI than 
patients with normal weight; similar results are seen 
in patients with severe obesity, thus suggesting the 
possible presence of the “obesity paradox” in coro-
nary artery disease. In the same meta-analysis, over-
weight patients had 30% lower mortality after ACS 
compared to patients with a normal BMI; obese pa-
tients had 40% lower mortality, and even severely 
obese subjects (BMI>40 kg/m2) had 30% lower mor-
tality compared to patients with a normal BMI.
In a study by Herrmann et al,9 after three years’ 
monitoring, post-AMI patients who were overweight 
or obese had better outcomes than normal or under-
weight patients with regard to the overall death rate. 
The same patients showed no difference in rates of 
cardiac death according to BMI. We can conclude 
that the difference in overall mortality between over-
weight and normal-weight individuals is due more to 
other comorbidities apart from coronary disease. In 
the above study, after multivariate analysis, obesity as 
determined by BMI was not an independent predic-
tor of mortality in patients with ST-elevation myocar-
dial infarction (STEMI).
The SYNERGY trial, which included 9000 pa-
tients with non-ST-elevation ACS,10 found that the 
annual mortality was greatest in underweight pa-
tients, improving with increasing BMI in overweight 
and obese patients, and levelling off in severely obese 
patients (BMI>40 kg/m2), creating the characteristic 
J-curve of the “obesity paradox”.
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In addition, a study by Angeras et al confirmed 
the findings of the preceding meta-analysis that pa-
tients who are overweight or obese have better sur-
vival compared with lean patients, and that this dif-
ference increases as we move further in time from the 
ACS episode, while there is no evidence that exces-
sively obese patients have lower mortality.11
In an analysis by Das et al that included more 
than 50,000 patients with STEMI, excessively obese 
patients, even though younger, with less extensive 
coronary artery disease, less impaired left ventricular 
systolic performance, and receiving the same quality 
of therapy, showed greater in-hospital mortality. Fur-
thermore, patients with normal weight had a higher 
rate of major bleeding.12
The main mechanisms of increased mortality in 
class III obese individuals (BMI>40 kg/m2) are in-
creased blood volume, increased filling pressures, 
and increased activation of the sympathetic system. In 
addition, the proinflammatory and thrombotic state 
make up an important mechanism of increased mor-
tality in extremely obese patients. Additionally, the 
increased cardiac mass predisposes to arrhythmias 
and sudden death, increasing mortality in these pa-
tients. At the same time, respiratory complications, 
such as aspiration pneumonia, sleep apnea, pulmo-
nary thromboembolism, and other hypoventilation 
syndromes, as well as the prolonged immobility, the 
difficulty of placing lines, and weight limitations in 
diagnostic and therapeutic examinations such as an-
giography, act as catalysts to increase mortality in pa-
tients after ACS, according to the study by Das et al.12 
In addition, a study by Wienbergen et al found that 
obese patients manifest coronary artery disease at a 
younger age.13
Regarding the therapeutic approach to patients 
with ACS, we see that overweight or obese patients 
receive a higher rate of treatment with aspirin, angio-
tensin-converting enzyme inhibitors, beta-blockers, 
and statins, and are more likely to stop smoking, ac-
cording to a meta-analysis by Steinberg et al.14 The 
same meta-analysis also confirmed that underweight 
patients were less likely to undergo catheterisation, 
angioplasty, or coronary artery bypass grafting. 
Summarizing the main reasons for the phenom-
enon of the “obesity paradox” in patients with acute 
coronary syndrome, overweight or obese patients are 
younger, have less extensive angiographic coronary 
artery disease, and usually adopt a more aggressive 
approach to risk factor modification, while obesity 
may protect against malignant ventricular arrhyth-
mias during and after AMI. reducing the risk of sud-
den death.7
Possible pathophysiological mechanisms behind 
the “obesity paradox” include the action of adipose 
tissue, as the largest endocrine organ, producing hor-
mones (leptin, adiponectin, resistin) with cardiopro-
tective effects after OEM.15 These effects are prob-
ably associated with less arrhythmogenesis and hence 
reduce the risk of sudden death in patients with 
ACS.16 Unlike underweight patients, low levels of 
adiponectin are found in the obese during the first 4 
weeks after AMI; therefore, obese patients have bet-
ter survival.
The guidelines suggest maintaining an ideal body 
weight with a BMI of 25 kg/m2 and a reduction in 
body weight if BMI>30 kg/m2 or when waist circum-
ference is >102 cm and >88 cm for women, as weight 
reduction improves several risk factors related to obe-
sity. Nevertheless, it has not yet been documented 
that a decrease in body weight per se reduces mortali-
ty in patients after STEMI.17 Moreover, the reduction 
in body weight achieved is usually poor, with weight 
reduction in obese patients post AMI of only 0.5% 
and corresponding weight reduction in severely obese 
patients of 3.5% after one year.18
In conclusion, overweight and obese patients ap-
pear to have a lower risk of death after the occur-
rence of an ACS; this is known as the “obesity par-
adox”. Young age, angiography at an earlier stage, 
and more aggressive treatment of ACS seems to be 
the aetiology of the “obesity paradox”. The data are 
based mainly on meta-analyses and especially retro-
spective studies; therefore, prospective randomized 
studies will be required to further evaluate the effect 
of obesity in patients with ACS.
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